BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19837768)

  • 1. 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
    Kaira K; Oriuchi N; Shimizu K; Tominaga H; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Mori M; Endo K
    J Nucl Med; 2009 Nov; 50(11):1770-6. PubMed ID: 19837768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.
    Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Mori M; Endo K
    AJR Am J Roentgenol; 2010 Nov; 195(5):1204-11. PubMed ID: 20966329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First clinical results of (D)-18F-Fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
    Burger IA; Zitzmann-Kolbe S; Pruim J; Friebe M; Graham K; Stephens A; Dinkelborg L; Kowal K; Schibli R; Luurtsema G; Maas B; Horn-Tutic M; Haerle SK; Wiegers J; Schaefer NG; Hany TF; von Schulthess GK
    J Nucl Med; 2014 Nov; 55(11):1778-85. PubMed ID: 25256060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer.
    Kaira K; Oriuchi N; Shimizu K; Ishikita T; Higuchi T; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
    Cancer Sci; 2009 Apr; 100(4):753-8. PubMed ID: 19141127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer.
    Kaira K; Endo M; Asakura K; Tsuya A; Nakamura Y; Naito T; Murakami H; Takahashi T; Yamamoto N
    Ann Nucl Med; 2010 Dec; 24(10):697-705. PubMed ID: 20824397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study.
    Kaira K; Oriuchi N; Otani Y; Shimizu K; Tanaka S; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Dobashi K; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
    Clin Cancer Res; 2007 Nov; 13(21):6369-78. PubMed ID: 17975149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting the prognostic value of preoperative (18)F-fluoro-2-deoxyglucose ( (18)F-FDG) positron emission tomography (PET) in early-stage (I & II) non-small cell lung cancers (NSCLC).
    Agarwal M; Brahmanday G; Bajaj SK; Ravikrishnan KP; Wong CY
    Eur J Nucl Med Mol Imaging; 2010 Apr; 37(4):691-8. PubMed ID: 19915840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection.
    Lee JW; Na JO; Kang DY; Lee SY; Lee SM
    Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer.
    Lopez Guerra JL; Gladish G; Komaki R; Gomez D; Zhuang Y; Liao Z
    J Nucl Med; 2012 Feb; 53(2):225-33. PubMed ID: 22241911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow hypermetabolism on 18F-FDG PET as a survival prognostic factor in non-small cell lung cancer.
    Prévost S; Boucher L; Larivée P; Boileau R; Bénard F
    J Nucl Med; 2006 Apr; 47(4):559-65. PubMed ID: 16595487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
    Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
    Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.
    Downey RJ; Akhurst T; Gonen M; Vincent A; Bains MS; Larson S; Rusch V
    J Clin Oncol; 2004 Aug; 22(16):3255-60. PubMed ID: 15310769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of dual-time-point 18F-FDG PET imaging in resectable non-small cell lung cancer.
    Shimizu K; Okita R; Saisho S; Yukawa T; Maeda A; Nojima Y; Nakata M
    Ann Nucl Med; 2015 Dec; 29(10):854-60. PubMed ID: 26254228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
    Hoang JK; Hoagland LF; Coleman RE; Coan AD; Herndon JE; Patz EF
    J Clin Oncol; 2008 Mar; 26(9):1459-64. PubMed ID: 18349396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
    J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.